Probiont is a deep-tech company focused on improving personalized cancer care through predictive immunotherapy efficacy assessment.
Our cancer-on-a-chip technology is purposed to emulate the effect of immune checkpoint inhibitor (ICI) cancer drugs, outside of the patient, prior to applying the treatment.
Get The News First
When We Will be Available in The Market
Problems and Solutions
There is no way to tell which cancer patient will react positively to ICI therapy.
Problems
01. Reduce Therapy
Globally $40B is spent unnecessarily on immune checkpoint inhibitor (ICI) therapy
02. Cost-Effective Tool
Need for cost-effective, reliable and simple to use tools for predicting ICI efficacy
03. Testing Methods
Pharma industry – growing need for in vitro testing methods for substituting animal tests in ICI drug development
Solutions
01. Cost Saving
Costs of cancer care is reduced by up to $300K/year for each patient identified as unsuitable for the treatment
02. Identify Before Treatment
Identifying the right type of treatment before using it. No wasting of time – getting personalized results within days
03. Fast Drug Development
Speeding up drug development based on personalised testing result
THE PRODUCT
PROBIONT TRIPLEPLEX IVD KIT
Tripleplex IVD kit is designed to work in a very straight forward and easy to use manner for the end users.
Product Roadmap
Get All Information About The PROBIONT
Our Team
BENEDEK POOR
CEO Founder, entrepreneur, inventor of core technology, worked in drug development, EU regulatory arena, former biotech CTO, bioengineer, PhD in chemistry.
MARK BAROK
MD, PhD in Medicine, 15 years experience in cancer therapy and drug development in Academia and Pharma.
Contact us
We’d love to hear from you! Send us a message using the form opposite, or email us. We’d love to hear from you! Send us a message using the form opposite, or email us.
